13F Holdings
中文EN

LNTH Lantheus Holdings, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1521036 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.4%
TTM net income YoY61.0%
TTM EPS YoY66.8%
Revenue 3-yr CAGR9.0%
Net income 3-yr CAGR37.4%

Margins

Gross margin61.3%
Operating margin18.6%
Net margin17.3%
FCF margin25.2%
EBITDA margin24.4%

Returns

ROE21.8%
ROA11.4%
ROIC (approx.)18.0%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets44.8%
Debt / equity0.42x
Current ratio3.25x
Interest coverage14.70x

Cash quality & payout

Operating cash flow / net income1.52x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.54B$1.53B$1.30B$935.06M$425.21M
Cost of revenue$599.66M$545.62M$586.89M$353.36M$237.51M
Gross profit$941.95M$988.29M$709.54M$581.70M$187.69M
R&D expense$177.31M$168.10M$77.71M$311.68M$44.97M
SG&A expense$275.12M$193.69M$125.46M$133.58M$150.40M
Operating income$310.83M$456.98M$364.64M$36.20M-$60.83M
Interest expense$19.75M$19.67M$20.02M$7.18M$7.75M
Pretax income$313.79M$430.98M$410.94M$26.72M-$75.04M
Income tax$80.23M$118.53M$84.28M-$1.35M-$3.76M
Net income$233.56M$312.44M$326.66M$28.07M-$71.28M
EBITDA$380.93M$521.60M$424.69M$84.12M-$18.54M
EPS (basic)3.464.524.790.41-1.06
EPS (diluted)3.414.364.650.40-1.06
Weighted avg. shares (diluted)68.44M71.65M70.24M70.67M67.49M
Balance sheet
Cash & equivalents$359.12M$914.49M$713.66M$417.24M$100.65M
Receivables$358.64M$321.26M$284.29M$213.40M$89.34M
Inventory$64.67M$68.03M$64.03M$35.48M$35.13M
Current assets$899.96M$1.33B$1.09B$677.62M$235.79M
PP&E, net$163.69M$176.80M$146.70M$122.17M$116.77M
Goodwill$239.52M$61.19M$61.19M$61.19M$61.19M
Intangibles$722.78M$161.76M$151.99M$315.29M$348.51M
Total assets$2.23B$1.98B$1.65B$1.32B$863.78M
Current liabilities$333.42M$240.53M$187.35M$247.70M$90.50M
Short-term debt$738,000$974,000$823,000$354,000$11.64M
Long-term debt$568.68M$565.28M$561.67M$557.71M$163.12M
Total debt$569.42M$566.25M$562.49M$558.07M$174.76M
Total liabilities$1.14B$892.33M$835.26M$874.11M$399.35M
Shareholders' equity$1.09B$1.09B$815.89M$447.15M$464.44M
Net debt$210.29M-$348.23M-$151.16M$140.82M$74.11M
Shares outstanding64.59M68.45M69.86M68.85M67.74M
Cash flow statement
Operating cash flow$390.14M$544.75M$305.26M$281.78M$53.92M
Capital expenditure$36.09M$51.62M$46.55M$18.35M$0
Free cash flow$354.05M$493.12M$258.70M$263.43M$53.92M
Investing cash flow-$627.17M-$226.01M$5.94M-$276.55M$3.68M
Financing cash flow-$316.58M-$118.54M-$13.06M$311.69M-$39.33M
Depreciation & amortization$70.10M$64.62M$60.04M$47.93M$42.29M
Stock-based compensation$85.56M$76.39M$50.51M$29.26M$15.93M
Share buybacks$300.02M$100.00M$0$75.00M$0

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.